Anti-obesity Drugs Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Drug Class, Application, Route of Administration, and Distribution Channel, and Geography

Description

List of Tables

According to our new research study on "Anti-obesity Drugs Market Forecast to 2031 -Global Analysis - by Type, Drug Class, Route of Administration, Application, Distribution Channel, and Geography," the market is anticipated to grow from US$ 15.85 billion in 2024 and is projected to reach US$ 177.27 billion by 2031; it is expected to register a CAGR of 35.3% during 2025-2031. Mounting prevalence of obesity and increased awareness and demand for weight management solutions are contributing to the growing anti-obesity drugs market size. However, the side effects and safety concerns hamper the anti-obesity drugs market growth. Further, precision medicine and personalized anti-obesity drug regimens is expected to bring in new anti-obesity drugs market trends in the coming years.

In terms of revenue, North America dominated the market in 2024. It is estimated to dominate the global market during the forecast period. The US is the largest market for anti-obesity drugs in the world. Chronic wounds associated with diabetes include foot, venous, and pressure ulcers. According to The International Journal of Tissue Repair and Regeneration, active or healed venous ulcers occur in 1% of the US population. As per the National Diabetes Statistics Report 2020, a publication of the Centers for Disease Control and Prevention (CDC), 34.2 million people of all ages in the US have diabetes, and ~1 million diabetics develop a foot ulcer each year, while 6-7 million diabetes patients develop ulcers in their lifetime. Thus, the rising incidence of diabetes and chronic wounds leads to an increase in demand for wound dressing and contributes to the anti-obesity drugs market growth during the forecast period. Companies in the US are focused on expanding their presence by adopting organic and inorganic strategies. In October 2021, Medline Industries announced an investment of US$ 77.5 million to build a new distribution center in Kansas.

Anti-obesity Drugs Market Analysis

Expansion in Emerging Economies to Provide Market Opportunities in Future

According to a Lancet study published in July 2023, approximately 450 million adults in India are expected to be overweight or obese by 2050. In 2021, more than half of the world's adults who were classified as overweight or obese lived in India, with 180 million affected individuals; China, with 402 million; Brazil, with 88 million; Russia, with 71 million; Mexico, with 58 million; Indonesia, with 52 million; and Egypt, with 41 million.

According to the World Obesity Federation, Vietnam, Indonesia, and Bangladesh are experiencing rising obesity prevalence, with a rate of 6-9% in recent decades. The mounting prevalence of obesity in emerging countries due to urbanization, sedentary lifestyles, and dietary changes has increased the demand for anti-obesity drugs. A large segment of the population remains undiagnosed or untreated, offering an underpenetrated market for pharmaceutical companies to introduce new therapies and expand their reach. Eli Lilly is preparing to launch its weight-loss and diabetes drug, tirzepatide (marketed as Mounjaro for diabetes and Zepbound for obesity), in India, Brazil, and Mexico by 2026.

Brazil is enhancing healthcare infrastructure and obesity management programs, fostering a supportive environment for the introduction and reimbursement of new anti-obesity medications. In April 2024, Brazil opened a laboratory in Hortolandia, Sao Paulo State, dedicated to producing medications for diabetes and obesity, including liraglutide, an active ingredient found in Ozempic. The EMS-operated plant will also produce semaglutide, a key ingredient in Ozempic, which has a patent valid until March 2026 and is already under review by Agencia Nacional de Vigilancia Sanitaria (ANVISA). With an investment of R$60 million (~US$ 10.93 million), this facility is the first of its kind in Brazil and supports the federal government's Health Economic-Industrial Complex initiatives.

According to the World Economic Forum, initial access to anti-obesity medications may be limited to private markets and out-of-pocket payments. Still, future insurance coverage and generic versions in middle-income countries could improve the accessibility of these medications. Thus, the rising obesity rates, supportive government initiatives, and product innovations are expected to create future growth opportunities for the market in emerging countries.

Anti-obesity Drugs Market Report Segmentation Analysis

Key segments that contributed to the derivation of the anti-obesity drugs market analysis are type, drug class, route of administration, application, and distribution channel.

Based on type, the anti-obesity drugs market is bifurcated into prescription and OTC. The prescription segment held relatively larger share of the market in 2024.

By drug class, the anti-obesity drugs market is segmented into GLP-1 agonists, lipase inhibitors, MC4R agonists, and others. The GLP-1 Agonist segment held the largest share of the market in 2024. GLP-1 agonists segment further subsegmented into Semaglutide, Liraglutide, Tirzepatide.

Based on application, the anti-obesity drugs market is categorized into appetite suppression, inhibition of fat absorption/digestive enzymes, metabolic enhancement, and combination. The appetite suppression segment held a largest share of the market in 2024.

In terms of route of administration, the anti-obesity drugs market is bifurcated into oral and parenteral. The oral segment dominated the market in 2024.

Per distribution channel, the anti-obesity drugs market is categorized into hospital pharmacies, online channel, and retail pharmacies. The hospital pharmacies segment dominated the market in 2024.

Anti-obesity Drugs Market: Competitive Landscape and Key Developments

Novo Nordisk AS, Eli Lilly and Co, GSK Plc, Rhythm Pharmaceuticals Inc, Currax Pharmaceuticals LLC., VIVUS LLC, AdvaCare Pharma USA LL, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, and F. Hoffmann-La Roche Ltd are among the key companies operating in the anti-obesity drugs market.

The World Health Organization, World Obesity Atlas, The U.S. Food and Drug Administration, The Lancet Journal, World Obesity Federation, World Economic Forum, Centers for Disease Control and Prevention (CDC), the International Diabetes Federation (IDF), the Organization for Economic Co-operation and Development (OECD) are primary and secondary sources referred to while preparing the anti-obesity drugs market report.

Product Code: TIPRE00006850

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Analyst Market Outlook

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
3.3 Assumptions and Limitations

4. Anti-Obesity Drugs Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Anti-Obesity Drugs Market - Key Market Dynamics

5.1 Anti-Obesity Drugs Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Mounting Prevalence of Obesity
- 5.2.2 Increased Awareness and Demand for Weight Management Solutions
5.3 Market Restraints
- 5.3.1 Side Effects and Safety Concerns
5.4 Market Opportunities
- 5.4.1 Expansion in Emerging Economies
5.5 Future Trends
- 5.5.1 Precision Medicine and Personalized Anti-Obesity Drug Regimens
5.6 Impact of Drivers and Restraints:

6. Anti-Obesity Drugs Market - Global Market Analysis

6.1 Anti-Obesity Drugs Market Revenue (US$ Million), 2021-2031
6.2 Anti-Obesity Drugs Market Forecast Analysis

7. Anti-Obesity Drugs Market Analysis - by Type

7.1 Prescription Drugs
- 7.1.1 Overview
- 7.1.2 Prescription Drugs: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.2 OTC Drugs
- 7.2.1 Overview
- 7.2.2 OTC Drugs: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)

8. Anti-Obesity Drugs Market Analysis - by Drug Class

8.1 GLP-1 Agonist
- 8.1.1 Overview
- 8.1.2 GLP-1 Agonist: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Lipase Inhibitors
- 8.2.1 Overview
- 8.2.2 Lipase Inhibitors: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
8.3 MC4R agonist
- 8.3.1 Overview
- 8.3.2 MC4R agonist: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Others
- 8.4.1 Overview
- 8.4.2 Others: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)

9. Anti-Obesity Drugs Market Analysis - by Application

9.1 Appetite Suppression
- 9.1.1 Overview
- 9.1.2 Appetite Suppression: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Inhibition of Fat Absorption or Digestive Enzymes
- 9.2.1 Overview
- 9.2.2 Inhibition of Fat Absorption or Digestive Enzymes: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Metabolic Enhancement
- 9.3.1 Overview
- 9.3.2 Metabolic Enhancement: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
9.4 Combination
- 9.4.1 Overview
- 9.4.2 Combination: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)

10. Anti-Obesity Drugs Market Analysis - by Route Of Administration

10.1 Oral
- 10.1.1 Overview
- 10.1.2 Oral: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
10.2 Parenteral
- 10.2.1 Overview
- 10.2.2 Parenteral: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)

11. Anti-Obesity Drugs Market Analysis - by Distribution Channel

11.1 Hospital Pharmacies
- 11.1.1 Overview
- 11.1.2 Hospital Pharmacies: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
11.2 Online Channel
- 11.2.1 Overview
- 11.2.2 Online Channel: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
11.3 Retail Pharmacies
- 11.3.1 Overview
- 11.3.2 Retail Pharmacies: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)

12. Anti-Obesity Drugs Market - Geographical Analysis

12.1 Overview
12.2 North America
- 12.2.1 North America Anti-Obesity Drugs Market Overview
- 12.2.2 North America: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
- 12.2.3 North America: Anti-Obesity Drugs Market Breakdown, by Type
  - 12.2.3.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Type
- 12.2.4 North America: Anti-Obesity Drugs Market Breakdown, by Drug Class
  - 12.2.4.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
    - 12.2.4.1.1 North America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.2.5 North America: Anti-Obesity Drugs Market Breakdown, by Application
  - 12.2.5.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Application
- 12.2.6 North America: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
  - 12.2.6.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
- 12.2.7 North America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  - 12.2.7.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
- 12.2.8 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
  - 12.2.8.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
  - 12.2.8.2 United States: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 12.2.8.2.1 United States: Anti-Obesity Drugs Market Breakdown, by Type
    - 12.2.8.2.2 United States: Anti-Obesity Drugs Market Breakdown, by Drug Class
      - 12.2.8.2.2.1 United States: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    - 12.2.8.2.3 United States: Anti-Obesity Drugs Market Breakdown, by Application
    - 12.2.8.2.4 United States: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
    - 12.2.8.2.5 United States: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  - 12.2.8.3 Canada: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 12.2.8.3.1 Canada: Anti-Obesity Drugs Market Breakdown, by Type
    - 12.2.8.3.2 Canada: Anti-Obesity Drugs Market Breakdown, by Drug Class
      - 12.2.8.3.2.1 Canada: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    - 12.2.8.3.3 Canada: Anti-Obesity Drugs Market Breakdown, by Application
    - 12.2.8.3.4 Canada: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
    - 12.2.8.3.5 Canada: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  - 12.2.8.4 Mexico: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 12.2.8.4.1 Mexico: Anti-Obesity Drugs Market Breakdown, by Type
    - 12.2.8.4.2 Mexico: Anti-Obesity Drugs Market Breakdown, by Drug Class
      - 12.2.8.4.2.1 Mexico: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    - 12.2.8.4.3 Mexico: Anti-Obesity Drugs Market Breakdown, by Application
    - 12.2.8.4.4 Mexico: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
    - 12.2.8.4.5 Mexico: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.3 Europe
- 12.3.1 Europe Anti-Obesity Drugs Market Overview
- 12.3.2 Europe: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
- 12.3.3 Europe: Anti-Obesity Drugs Market Breakdown, by Type
  - 12.3.3.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Type
- 12.3.4 Europe: Anti-Obesity Drugs Market Breakdown, by Drug Class
  - 12.3.4.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
    - 12.3.4.1.1 Europe: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.3.5 Europe: Anti-Obesity Drugs Market Breakdown, by Application
  - 12.3.5.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Application
- 12.3.6 Europe: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
  - 12.3.6.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
- 12.3.7 Europe: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  - 12.3.7.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
- 12.3.8 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
  - 12.3.8.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
  - 12.3.8.2 Germany: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 12.3.8.2.1 Germany: Anti-Obesity Drugs Market Breakdown, by Type
    - 12.3.8.2.2 Germany: Anti-Obesity Drugs Market Breakdown, by Drug Class
      - 12.3.8.2.2.1 Germany: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    - 12.3.8.2.3 Germany: Anti-Obesity Drugs Market Breakdown, by Application
    - 12.3.8.2.4 Germany: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
    - 12.3.8.2.5 Germany: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  - 12.3.8.3 United Kingdom: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 12.3.8.3.1 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Type
    - 12.3.8.3.2 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Drug Class
      - 12.3.8.3.2.1 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    - 12.3.8.3.3 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Application
    - 12.3.8.3.4 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
    - 12.3.8.3.5 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  - 12.3.8.4 France: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 12.3.8.4.1 France: Anti-Obesity Drugs Market Breakdown, by Type
    - 12.3.8.4.2 France: Anti-Obesity Drugs Market Breakdown, by Drug Class
      - 12.3.8.4.2.1 France: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    - 12.3.8.4.3 France: Anti-Obesity Drugs Market Breakdown, by Application
    - 12.3.8.4.4 France: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
    - 12.3.8.4.5 France: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  - 12.3.8.5 Spain: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 12.3.8.5.1 Spain: Anti-Obesity Drugs Market Breakdown, by Type
    - 12.3.8.5.2 Spain: Anti-Obesity Drugs Market Breakdown, by Drug Class
      - 12.3.8.5.2.1 Spain: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    - 12.3.8.5.3 Spain: Anti-Obesity Drugs Market Breakdown, by Application
    - 12.3.8.5.4 Spain: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
    - 12.3.8.5.5 Spain: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  - 12.3.8.6 Italy: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 12.3.8.6.1 Italy: Anti-Obesity Drugs Market Breakdown, by Type
    - 12.3.8.6.2 Italy: Anti-Obesity Drugs Market Breakdown, by Drug Class
      - 12.3.8.6.2.1 Italy: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    - 12.3.8.6.3 Italy: Anti-Obesity Drugs Market Breakdown, by Application
    - 12.3.8.6.4 Italy: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
    - 12.3.8.6.5 Italy: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  - 12.3.8.7 Rest of Europe: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 12.3.8.7.1 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Type
    - 12.3.8.7.2 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Drug Class
      - 12.3.8.7.2.1 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    - 12.3.8.7.3 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Application
    - 12.3.8.7.4 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
    - 12.3.8.7.5 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.4 Asia Pacific
- 12.4.1 Asia Pacific Anti-Obesity Drugs Market Overview
- 12.4.2 Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
- 12.4.3 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Type
  - 12.4.3.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Type
- 12.4.4 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Drug Class
  - 12.4.4.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
    - 12.4.4.1.1 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.4.5 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Application
  - 12.4.5.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Application
- 12.4.6 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
  - 12.4.6.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
- 12.4.7 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  - 12.4.7.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
- 12.4.8 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
  - 12.4.8.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
  - 12.4.8.2 China: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 12.4.8.2.1 China: Anti-Obesity Drugs Market Breakdown, by Type
    - 12.4.8.2.2 China: Anti-Obesity Drugs Market Breakdown, by Drug Class
      - 12.4.8.2.2.1 China: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    - 12.4.8.2.3 China: Anti-Obesity Drugs Market Breakdown, by Application
    - 12.4.8.2.4 China: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
    - 12.4.8.2.5 China: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  - 12.4.8.3 Japan: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 12.4.8.3.1 Japan: Anti-Obesity Drugs Market Breakdown, by Type
    - 12.4.8.3.2 Japan: Anti-Obesity Drugs Market Breakdown, by Drug Class
      - 12.4.8.3.2.1 Japan: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    - 12.4.8.3.3 Japan: Anti-Obesity Drugs Market Breakdown, by Application
    - 12.4.8.3.4 Japan: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
    - 12.4.8.3.5 Japan: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  - 12.4.8.4 India: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 12.4.8.4.1 India: Anti-Obesity Drugs Market Breakdown, by Type
    - 12.4.8.4.2 India: Anti-Obesity Drugs Market Breakdown, by Drug Class
      - 12.4.8.4.2.1 India: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    - 12.4.8.4.3 India: Anti-Obesity Drugs Market Breakdown, by Application
    - 12.4.8.4.4 India: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
    - 12.4.8.4.5 India: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  - 12.4.8.5 Australia: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 12.4.8.5.1 Australia: Anti-Obesity Drugs Market Breakdown, by Type
    - 12.4.8.5.2 Australia: Anti-Obesity Drugs Market Breakdown, by Drug Class
      - 12.4.8.5.2.1 Australia: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    - 12.4.8.5.3 Australia: Anti-Obesity Drugs Market Breakdown, by Application
    - 12.4.8.5.4 Australia: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
    - 12.4.8.5.5 Australia: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  - 12.4.8.6 South Korea: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 12.4.8.6.1 South Korea: Anti-Obesity Drugs Market Breakdown, by Type
    - 12.4.8.6.2 South Korea: Anti-Obesity Drugs Market Breakdown, by Drug Class
      - 12.4.8.6.2.1 South Korea: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    - 12.4.8.6.3 South Korea: Anti-Obesity Drugs Market Breakdown, by Application
    - 12.4.8.6.4 South Korea: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
    - 12.4.8.6.5 South Korea: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  - 12.4.8.7 Rest of APAC: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 12.4.8.7.1 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Type
    - 12.4.8.7.2 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Drug Class
      - 12.4.8.7.2.1 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    - 12.4.8.7.3 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Application
    - 12.4.8.7.4 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
    - 12.4.8.7.5 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.5 Middle East and Africa
- 12.5.1 Middle East and Africa Anti-Obesity Drugs Market Overview
- 12.5.2 Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
- 12.5.3 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Type
  - 12.5.3.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Type
- 12.5.4 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Drug Class
  - 12.5.4.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
    - 12.5.4.1.1 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.5.5 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Application
  - 12.5.5.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Application
- 12.5.6 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
  - 12.5.6.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
- 12.5.7 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  - 12.5.7.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
- 12.5.8 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
  - 12.5.8.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
  - 12.5.8.2 Saudi Arabia: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 12.5.8.2.1 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Type
    - 12.5.8.2.2 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Drug Class
      - 12.5.8.2.2.1 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    - 12.5.8.2.3 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Application
    - 12.5.8.2.4 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
    - 12.5.8.2.5 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  - 12.5.8.3 South Africa: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 12.5.8.3.1 South Africa: Anti-Obesity Drugs Market Breakdown, by Type
    - 12.5.8.3.2 South Africa: Anti-Obesity Drugs Market Breakdown, by Drug Class
      - 12.5.8.3.2.1 South Africa: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    - 12.5.8.3.3 South Africa: Anti-Obesity Drugs Market Breakdown, by Application
    - 12.5.8.3.4 South Africa: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
    - 12.5.8.3.5 South Africa: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  - 12.5.8.4 United Arab Emirates: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 12.5.8.4.1 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Type
    - 12.5.8.4.2 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Drug Class
      - 12.5.8.4.2.1 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    - 12.5.8.4.3 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Application
    - 12.5.8.4.4 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
    - 12.5.8.4.5 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  - 12.5.8.5 Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 12.5.8.5.1 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Type
    - 12.5.8.5.2 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Drug Class
      - 12.5.8.5.2.1 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    - 12.5.8.5.3 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Application
    - 12.5.8.5.4 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
    - 12.5.8.5.5 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.6 South and Central America
- 12.6.1 South and Central America Anti-Obesity Drugs Market Overview
- 12.6.2 South and Central America: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
- 12.6.3 South and Central America: Anti-Obesity Drugs Market Breakdown, by Type
  - 12.6.3.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Type
- 12.6.4 South and Central America: Anti-Obesity Drugs Market Breakdown, by Drug Class
  - 12.6.4.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
    - 12.6.4.1.1 South and Central America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.6.5 South and Central America: Anti-Obesity Drugs Market Breakdown, by Application
  - 12.6.5.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Application
- 12.6.6 South and Central America: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
  - 12.6.6.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
- 12.6.7 South and Central America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  - 12.6.7.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
- 12.6.8 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
  - 12.6.8.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
  - 12.6.8.2 Brazil: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 12.6.8.2.1 Brazil: Anti-Obesity Drugs Market Breakdown, by Type
    - 12.6.8.2.2 Brazil: Anti-Obesity Drugs Market Breakdown, by Drug Class
      - 12.6.8.2.2.1 Brazil: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    - 12.6.8.2.3 Brazil: Anti-Obesity Drugs Market Breakdown, by Application
    - 12.6.8.2.4 Brazil: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
    - 12.6.8.2.5 Brazil: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  - 12.6.8.3 Argentina: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 12.6.8.3.1 Argentina: Anti-Obesity Drugs Market Breakdown, by Type
    - 12.6.8.3.2 Argentina: Anti-Obesity Drugs Market Breakdown, by Drug Class
      - 12.6.8.3.2.1 Argentina: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    - 12.6.8.3.3 Argentina: Anti-Obesity Drugs Market Breakdown, by Application
    - 12.6.8.3.4 Argentina: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
    - 12.6.8.3.5 Argentina: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  - 12.6.8.4 Rest of South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 12.6.8.4.1 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Type
    - 12.6.8.4.2 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Drug Class
      - 12.6.8.4.2.1 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    - 12.6.8.4.3 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Application
    - 12.6.8.4.4 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
    - 12.6.8.4.5 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel

13. Industry Landscape

13.1 Overview
13.2 New Product Development/Approval
13.3 Other Business Strategies

14. Company Profiles

14.1 Novo Nordisk AS
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
14.2 Eli Lilly and Co
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 GSK Plc
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
14.4 Rhythm Pharmaceuticals Inc
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Currax Pharmaceuticals LLC.
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 VIVUS LLC
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 AdvaCare Pharma USA LLC
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
14.8 Teva Pharmaceutical Industries Ltd
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
14.9 Sun Pharmaceutical Industries Ltd
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 F. Hoffmann-La Roche Ltd
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis

15. Appendix

15.1 About The Insight Partners
15.2 Glossary of Terms